Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Collecchi

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Oncology|January 1, 1988
Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancerM Esposito, E Campora, M Repetto, et al.
Cancer Science|April 24, 2009
Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapyAlessandro Sgambato, Andrea Camerini, Paola Collecchi, et al.
Medical Oncology (Northwood, London, England)|January 22, 2014
VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinomaFrancesca Lessi, Chiara Maria Mazzanti, Sara Tomei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancerE Baldini, G Gardin, P G Giannessi, et al.
Annals of the New York Academy of Sciences|November 30, 1993
Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancerG Mariani, P Collecchi, L Giuliani, et al.
The American Journal of Surgical Pathology|November 29, 2007
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progressionClaudio Di Cristofano, Andrea Minervini, Michele Menicagli, et al.
Endocrine-Related Cancer|September 17, 2009
Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomasF Cetani, E Pardi, C Banti, et al.
The Journal of Clinical Endocrinology and Metabolism|December 30, 2004
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genesRossella Elisei, Agnese Vivaldi, Laura Agate, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1993
Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancerG Mariani, A Cei, P Collecchi, et al.
International Journal of Cancer|December 14, 2006
High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosisGrazia Lombardi, Claudio Di Cristofano, Alessandra Capodanno, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Oncology|January 1, 1988
Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancerM Esposito, E Campora, M Repetto, et al.
Cancer Science|April 24, 2009
Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapyAlessandro Sgambato, Andrea Camerini, Paola Collecchi, et al.
Medical Oncology (Northwood, London, England)|January 22, 2014
VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinomaFrancesca Lessi, Chiara Maria Mazzanti, Sara Tomei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancerE Baldini, G Gardin, P G Giannessi, et al.
Annals of the New York Academy of Sciences|November 30, 1993
Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancerG Mariani, P Collecchi, L Giuliani, et al.
The American Journal of Surgical Pathology|November 29, 2007
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progressionClaudio Di Cristofano, Andrea Minervini, Michele Menicagli, et al.
Endocrine-Related Cancer|September 17, 2009
Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomasF Cetani, E Pardi, C Banti, et al.
The Journal of Clinical Endocrinology and Metabolism|December 30, 2004
All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genesRossella Elisei, Agnese Vivaldi, Laura Agate, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1993
Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancerG Mariani, A Cei, P Collecchi, et al.
International Journal of Cancer|December 14, 2006
High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosisGrazia Lombardi, Claudio Di Cristofano, Alessandra Capodanno, et al.
Pageof 6